ArticleFrontiers in immunology2024

Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States.

Andong Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.